Schroeder, R.P.J., de Visser, M., van Weerden, W.M., de Ridder, C.M.A., Reneman, S., Melis, M., Breeman, W.A.P., Krenning, E.P. and de Jong, M. (2010) Androgen-Regulated Gastrin-Releasing Peptide Receptor Expression in Androgen-Depen- dent Human Prostate Tumor Xenografts. International Journal of Cancer, 126, 2826- 2834.
https://doi.org/10.1002/ijc.25000

has been cited by the following article:

• TITLE: Synthesis and Radiation Dosimetry of [68Ga]-Ga-Lys1, Lys3-DOTA-Bombesin (1,14) Antagonist for PET-Imaging, as a Potential Theragnostic Tracer in Oncology

  AUTHORS: Juan C. Manrique-Arias, Quetzali Pitalua-Cortes, Roberto Pedrero-Piedras, Géiser Rodríguez-Mena, Tessy López, Cristian Cabezas-Ortiz, Osvaldo García-Pérez

  KEYWORDS: Radiation Dosimetry, Biodistribution, PET Imaging, Radiopharmaceutical, Lys1, Lys3-DOTA-BBN (1, 14), Bombesin Analogs

  JOURNAL NAME: Journal of Encapsulation and Adsorption Sciences, Vol.10 No.2, June 22, 2020

  ABSTRACT: This Bombesin (BBN), a tetradecapeptide analog of human gastrin-releasing peptide (GRP) with a high binding affinity for GRP receptors (GRPR), is over- expressed in early stages of androgen-dependent prostate carcinomas, but not in advanced stages. Therefore, there is a need to develop effective tracers for the accurate and specific detection of this disease. The objective of this study was to evaluate Lys1, Lys3-DOTA-BBN (1,14) analog with the radiolabeled positron emitter [68Ga]-Ga-BBN for receptor imaging with PET, and to determine its biodistribution and radiation dosimetry using whole-body (WB) PET scans in healthy volunteers. The highest uptake was in the pancreas, followed by urinary bladder. The critical organ was pancreas with a mean absorbed dose of 206 ± 0.7, 210 ± 0.7, 120 ± 0.9, 390.23 ± 0.6 μGy/MBq and the effective doses were estimated as 73.2 ± 0.6, 49.8 ± 0.3 μGy/MBq (women and men, respectively).